Epilepsy: Perampanel - New promise for refractory epilepsy?

Nature Reviews Neurology

Volumn 8, Issue 12, 2012, Pages 661-662

  Löscher, Wolfgang ^a   Schmidt, Dieter ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b Epilepsy Research Group   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; CARBAMAZEPINE; FELBAMATE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; OXCARBAZEPINE; PERAMPANEL; PHENYTOIN; PLACEBO; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADJUVANT THERAPY; DIZZINESS; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPSY; FALLING; FATIGUE; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE;

ANTICONVULSANTS; CLINICAL TRIALS, PHASE III AS TOPIC; EPILEPSY; HUMANS; PYRIDONES;

EID: 84870775724     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.222     Document Type: Short Survey

References (10)

1. Löscher, W. & Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52, 657-678 (2011).
2. Beyenburg, S., Stavem, K. & Schmidt, D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 51, 7-26 (2010).
3. French, J. A. et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79, 589-596 (2012).
4. French, J. A. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia http://dx.doi.org/10.1111/j.1528-1167.2012. 03638.x.
5. Krauss, G. L. et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78, 1408-1415 (2012).
6. Rogawski, M. A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 11, 56-63 (2011).
7. Löscher, W. & Schmidt, D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res. 17, 95-134 (1994).
8. Bialer, M. & White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 9, 68-82 (2010).
9. European Medicines Agency. Fycompa\- summary of product characteristics. European Medicines Agency [online], http://www.ema. europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002434/WC500130815.pdf (2012).
10. Krauss, G. L. et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia http://dx.doi.org/10.1111/j.1528- 1167. 2012.03648.x.